{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:59:36Z","timestamp":1781135976901,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Key Disciplines Project","award":["2024ZDJS137"],"award-info":[{"award-number":["2024ZDJS137"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47972-y","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T06:14:14Z","timestamp":1776579254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal machine learning integrates clinical and comorbidity data to predict breast cancer prognosis and treatment outcomes"],"prefix":"10.1038","volume":"16","author":[{"given":"Yongsheng","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tet Khuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana Muhammad","family":"Ehsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmugam","family":"Kamalanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan Kuen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"47972_CR1","unstructured":"Edge, S. B., Byrd, D. R., Compton, C. C., Fritz, A. G., Greene, F. L., & Trotti, A. (Eds.). (2010). AJCC Cancer Staging Manual (7th ed.). Springer. https:\/\/link.springer.com\/book\/9780387884424"},{"issue":"11\u201312","key":"47972_CR2","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/sj.bjc.6690279","volume":"79","author":"W Sauerbrei","year":"1999","unstructured":"Sauerbrei, W., Royston, P., Bojar, H., Schmoor, C. & Schumacher, M. Modelling the effects of standard prognostic factors in node-positive breast cancer. Br. J. Cancer 79(11\u201312), 1752\u20131760. https:\/\/doi.org\/10.1038\/sj.bjc.6690279 (1999).","journal-title":"Br. J. Cancer"},{"issue":"2","key":"47972_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ijc.28683","volume":"135","author":"C Webber","year":"2014","unstructured":"Webber, C. et al. Improving the TNM classification: Findings from a 10-year continuous literature review. Int. J. Cancer 135(2), 371\u2013378. https:\/\/doi.org\/10.1002\/ijc.28683 (2014).","journal-title":"Int. J. Cancer"},{"issue":"1","key":"47972_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/2159-8290.CD-18-0065","volume":"9","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models. Cancer Discov. 9(1), 96\u2013113. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0065 (2019).","journal-title":"Cancer Discov."},{"issue":"12","key":"47972_CR5","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1200\/JCO.2010.30.3677","volume":"29","author":"JMS Bartlett","year":"2011","unstructured":"Bartlett, J. M. S. et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: A prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J. Clin. Oncol. 29(12), 1531\u20131538. https:\/\/doi.org\/10.1200\/JCO.2010.30.3677 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"47972_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/cgt.2013.13","volume":"20","author":"M Dietel","year":"2013","unstructured":"Dietel, M. et al. Predictive molecular pathology and its role in targeted cancer therapy: A review focussing on clinical relevance. Cancer Gene Ther. 20(4), 211\u2013221. https:\/\/doi.org\/10.1038\/cgt.2013.13 (2013).","journal-title":"Cancer Gene Ther."},{"issue":"21","key":"47972_CR7","first-page":"7641","volume":"63","author":"HM M\u00fcller","year":"2003","unstructured":"M\u00fcller, H. M. et al. DNA methylation in serum of breast cancer patients: An independent prognostic marker. Cancer Res. 63(21), 7641\u20137645 (2003).","journal-title":"Cancer Res."},{"issue":"1","key":"47972_CR8","doi-asserted-by":"publisher","first-page":"R118","DOI":"10.1186\/bcr3243","volume":"14","author":"M\u00fcller, V., Riethdorf, S., Rack, B., Janni, W., Fasching, P., Solomayer, E., Aktas, B., Kasimir-Bauer, S., Pantel, K., Fehm, T., & DETECT Study Group","year":"2012","unstructured":"M\u00fcller, V., Riethdorf, S., Rack, B., Janni, W., Fasching, P., Solomayer, E., Aktas, B., Kasimir-Bauer, S., Pantel, K., Fehm, T., & DETECT Study Group. Prognostic impact of circulating tumor cells assessed with the Cell Search Assay\u2122 and AdnaTest Breast\u2122 in metastatic breast cancer patients: The DETECT study. Breast Cancer Res. 14(1), R118. https:\/\/doi.org\/10.1186\/bcr3243 (2012).","journal-title":"Breast Cancer Res."},{"issue":"20","key":"47972_CR9","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.ccr-14-0458","volume":"20","author":"T Tramm","year":"2014","unstructured":"Tramm, T. et al. Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: A study of gene expression in the DBCG82bc cohort. Clin. Cancer Res. 20(20), 5272\u20135280. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-0458 (2014).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"47972_CR10","first-page":"11","volume":"1","author":"DC Dale","year":"2003","unstructured":"Dale, D. C. Poor prognosis in elderly patients with cancer: The role of bias and undertreatment. J. Support. Oncol. 1(1), 11\u201317 (2003).","journal-title":"J. Support. Oncol."},{"issue":"3","key":"47972_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10549-012-2073-x","volume":"134","author":"S Niraula","year":"2012","unstructured":"Niraula, S., Ocana, A., Ennis, M. & Goodwin, P. J. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: A meta-analysis. Breast Cancer Res. Treat. 134(3), 769\u2013781. https:\/\/doi.org\/10.1007\/s10549-012-2073-x (2012).","journal-title":"Breast Cancer Res. Treat."},{"issue":"9805","key":"47972_CR12","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/S0140-6736(11)61539-0","volume":"378","author":"JS Reis-Filho","year":"2011","unstructured":"Reis-Filho, J. S. & Pusztai, L. Gene expression profiling in breast cancer: Classification, prognostication, and prediction. The Lancet 378(9805), 1812\u20131823. https:\/\/doi.org\/10.1016\/S0140-6736(11)61539-0 (2011).","journal-title":"The Lancet"},{"issue":"25","key":"47972_CR13","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ van de Vijver","year":"2002","unstructured":"van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999\u20132009. https:\/\/doi.org\/10.1056\/NEJMoa021967 (2002).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"47972_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10549-010-1331-z","volume":"127","author":"G Tang","year":"2011","unstructured":"Tang, G. et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Breast Cancer Res. Treat. 127(1), 133\u2013142. https:\/\/doi.org\/10.1007\/s10549-010-1331-z (2011).","journal-title":"Breast Cancer Res. Treat."},{"issue":"11","key":"47972_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783\u2013792. https:\/\/doi.org\/10.1056\/NEJM200103153441101 (2001).","journal-title":"N. Engl. J. Med."},{"key":"47972_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fmed.2017.00227","volume":"4","author":"G Turashvili","year":"2017","unstructured":"Turashvili, G. & Brogi, E. Tumor heterogeneity in breast cancer. Front. Med. 4, 227. https:\/\/doi.org\/10.3389\/fmed.2017.00227 (2017).","journal-title":"Front. Med."},{"issue":"6","key":"47972_CR17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1037\/0022-006X.74.6.1143","volume":"74","author":"MH Antoni","year":"2006","unstructured":"Antoni, M. H. et al. How stress management improves quality of life after treatment for breast cancer. J. Consult. Clin. Psychol. 74(6), 1143\u20131152. https:\/\/doi.org\/10.1037\/0022-006X.74.6.1143 (2006).","journal-title":"J. Consult. Clin. Psychol."},{"issue":"18","key":"47972_CR18","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/jco.2005.02.3028","volume":"24","author":"SH Giordano","year":"2006","unstructured":"Giordano, S. H., Duan, Z., Kuo, Y. F., Hortobagyi, G. N. & Goodwin, J. S. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J. Clin. Oncol. 24(18), 2750\u20132756. https:\/\/doi.org\/10.1200\/jco.2005.02.3028 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"47972_CR19","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817\u20132826. https:\/\/doi.org\/10.1056\/NEJMoa041588 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"47972_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jnci\/djj329","volume":"98","author":"M Buyse","year":"2006","unstructured":"Buyse, M. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. JNCI J. Natl. Cancer Inst. 98(17), 1183\u20131192. https:\/\/doi.org\/10.1093\/jnci\/djj329 (2006).","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"21","key":"47972_CR21","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","volume":"373","author":"JA Sparano","year":"2015","unstructured":"Sparano, J. A. et al. Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373(21), 2005\u20132014. https:\/\/doi.org\/10.1056\/NEJMoa1510764 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"47972_CR22","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/cncr.26646","volume":"118","author":"M Extermann","year":"2012","unstructured":"Extermann, M. et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118(13), 3377\u20133386. https:\/\/doi.org\/10.1002\/cncr.26646 (2012).","journal-title":"Cancer"},{"issue":"23","key":"47972_CR23","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1200\/JCO.2008.20.0725","volume":"27","author":"PJ Goodwin","year":"2009","unstructured":"Goodwin, P. J., Ennis, M., Pritchard, K. I., Koo, J. & Hood, N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J. Clin. Oncol. 27(23), 3757\u20133763. https:\/\/doi.org\/10.1200\/JCO.2008.20.0725 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"47972_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/08258597241253933","volume":"40","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z., Lovell, A., Subramaniam, D. S. & Hinyard, L. The impact of palliative care consultation on aggressive medical interventions in end-of-life among patients with metastatic breast cancer: Insights from the U.S. national patient sample. J. Palliative Care 40(1), 8\u201317. https:\/\/doi.org\/10.1177\/08258597241253933 (2025).","journal-title":"J. Palliative Care"},{"key":"47972_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clnesp.2021.03.037","volume":"43","author":"M Carri\u00e7o","year":"2021","unstructured":"Carri\u00e7o, M., Sousa Guerreiro, C. & Parreira, A. The validity of the Patient-Generated Subjective Global Assessment Short-form\u00a9 in cancer patients undergoing chemotherapy. Clin. Nutr. ESPEN 43, 296\u2013301. https:\/\/doi.org\/10.1016\/j.clnesp.2021.03.037 (2021).","journal-title":"Clin. Nutr. ESPEN"},{"issue":"33","key":"47972_CR26","doi-asserted-by":"publisher","first-page":"53137","DOI":"10.18632\/oncotarget.10614","volume":"7","author":"RM Hallett","year":"2016","unstructured":"Hallett, R. M. et al. Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer. Oncotarget 7(33), 53137\u201353152. https:\/\/doi.org\/10.18632\/oncotarget.10614 (2016).","journal-title":"Oncotarget"},{"issue":"6","key":"47972_CR27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/annonc\/mdl064","volume":"17","author":"BC Pestalozzi","year":"2006","unstructured":"Pestalozzi, B. C. et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann. Oncol. 17(6), 935\u2013944. https:\/\/doi.org\/10.1093\/annonc\/mdl064 (2006).","journal-title":"Ann. Oncol."},{"key":"47972_CR28","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2147\/cia.s414727","volume":"18","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. The prognostic value of the age-adjusted Charlson Comorbidity Index among the elderly with breast cancer. Clin. Interv. Aging 18, 1163\u20131174. https:\/\/doi.org\/10.2147\/cia.s414727 (2023).","journal-title":"Clin. Interv. Aging"},{"issue":"6","key":"47972_CR29","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2214\/ajr.126.6.1130","volume":"126","author":"JN Wolfe","year":"1976","unstructured":"Wolfe, J. N. Breast patterns as an index of risk for developing breast cancer. AJR Am. J. Roentgenol. 126(6), 1130\u20131137. https:\/\/doi.org\/10.2214\/ajr.126.6.1130 (1976).","journal-title":"AJR Am. J. Roentgenol."},{"issue":"12","key":"47972_CR30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin, P. et al. Radiomics: The bridge between medical imaging and personalized medicine. Nat. Rev. Clin. Oncol. 14(12), 749\u2013762. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"47972_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11136-010-9793-3","volume":"20","author":"M Brundage","year":"2011","unstructured":"Brundage, M. et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: Implications for clinicians and quality of life researchers. Qual. Life Res. 20(5), 653\u2013664. https:\/\/doi.org\/10.1007\/s11136-010-9793-3 (2011).","journal-title":"Qual. Life Res."},{"issue":"5","key":"47972_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 40(5), 373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8 (1987).","journal-title":"J. Chronic Dis."},{"issue":"4","key":"47972_CR33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10741-008-9088-8","volume":"13","author":"IS Anand","year":"2008","unstructured":"Anand, I. S. Heart failure and anemia: Mechanisms and pathophysiology. Heart Fail. Rev. 13(4), 379\u2013386. https:\/\/doi.org\/10.1007\/s10741-008-9088-8 (2008).","journal-title":"Heart Fail. Rev."},{"issue":"1","key":"47972_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser, A., Steiner, C., Harris, D. R. & Coffey, R. M. Comorbidity measures for use with administrative data. Med. Care. 36(1), 8\u201327. https:\/\/doi.org\/10.1097\/00005650-199801000-00004 (1998).","journal-title":"Med. Care."},{"issue":"1","key":"47972_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-018-1424-4","volume":"16","author":"W Zhou","year":"2018","unstructured":"Zhou, W., Chen, S., Xu, F. & Zeng, X. Survival benefit of pure dose-dense chemotherapy in breast cancer: A meta-analysis of randomized controlled trials. World J. Surg. Oncol. 16(1), 144. https:\/\/doi.org\/10.1186\/s12957-018-1424-4 (2018).","journal-title":"World J. Surg. Oncol."},{"issue":"5","key":"47972_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials. J. Natl. Cancer Inst. 85(5), 365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365 (1993).","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"47972_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell 168(4), 613\u2013628. https:\/\/doi.org\/10.1016\/j.cell.2017.01.018 (2017).","journal-title":"Cell"},{"key":"47972_CR38","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1186\/bcr2464","volume":"12","author":"GC Wishart","year":"2010","unstructured":"Wishart, G. C., Azzato, E. M., Greenberg, D. C., Caldas, C. & Pharoah, P. D. P. PREDICT: A new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 12, R1. https:\/\/doi.org\/10.1186\/bcr2464 (2010).","journal-title":"Breast Cancer Res."},{"issue":"6797","key":"47972_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406(6797), 747\u2013752. https:\/\/doi.org\/10.1038\/35021093 (2000).","journal-title":"Nature"},{"issue":"10","key":"47972_CR40","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/annonc\/mdw262","volume":"27","author":"MV Dieci","year":"2016","unstructured":"Dieci, M. V. et al. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann. Oncol. 27(10), 1867\u20131873. https:\/\/doi.org\/10.1093\/annonc\/mdw262 (2016).","journal-title":"Ann. Oncol."},{"issue":"4","key":"47972_CR41","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ejca.2011.12.025","volume":"48","author":"MC Asselin","year":"2012","unstructured":"Asselin, M. C., O\u2019Connor, J. P. B., Boellaard, R., Thacker, N. A. & Jackson, A. Quantifying heterogeneity in human tumours using MRI and PET. Eur. J. Cancer 48(4), 447\u2013455. https:\/\/doi.org\/10.1016\/j.ejca.2011.12.025 (2012).","journal-title":"Eur. J. Cancer"},{"key":"47972_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2018.04.011","volume":"98","author":"MN Mills","year":"2018","unstructured":"Mills, M. N. et al. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. Eur. J. Cancer 98, 48\u201358. https:\/\/doi.org\/10.1016\/j.ejca.2018.04.011 (2018).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"47972_CR43","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.4143\/crt.2015.456","volume":"48","author":"E Jwa","year":"2016","unstructured":"Jwa, E. et al. Locoregional recurrence by tumor biology in breast cancer patients after preoperative chemotherapy and breast conservation treatment. Cancer Res. Treat. 48(4), 1363\u20131372. https:\/\/doi.org\/10.4143\/crt.2015.456 (2016).","journal-title":"Cancer Res. Treat."},{"issue":"16","key":"47972_CR44","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1158\/1078-0432.ccr-14-2898","volume":"21","author":"C Speers","year":"2015","unstructured":"Speers, C. et al. Development and validation of a novel radiosensitivity signature in human breast cancer. Clin. Cancer Res. 21(16), 3667\u20133677. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-2898 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"47972_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.2011.535","volume":"106","author":"EK Watson","year":"2012","unstructured":"Watson, E. K. et al. Personalised cancer follow-up: Risk stratification, needs assessment or both?. Br. J. Cancer 106(1), 1\u20135. https:\/\/doi.org\/10.1038\/bjc.2011.535 (2012).","journal-title":"Br. J. Cancer"},{"issue":"12","key":"47972_CR46","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/bioinformatics\/btv088","volume":"31","author":"C Xu","year":"2015","unstructured":"Xu, C. & Su, Z. Identification of cell types from single-cell transcriptomes using a novel clustering method. Bioinformatics 31(12), 1974\u20131980. https:\/\/doi.org\/10.1093\/bioinformatics\/btv088 (2015).","journal-title":"Bioinformatics"},{"issue":"1","key":"47972_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GXY Zheng","year":"2017","unstructured":"Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8(1), 14049. https:\/\/doi.org\/10.1038\/ncomms14049 (2017).","journal-title":"Nat. Commun."},{"key":"47972_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103100","volume":"62","author":"A Alba-Bernal","year":"2020","unstructured":"Alba-Bernal, A. et al. Challenges and achievements of liquid biopsy technologies employed in early breast cancer. EBioMedicine 62, 103100. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103100 (2020).","journal-title":"EBioMedicine"},{"issue":"2","key":"47972_CR49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","volume":"124","author":"L Keller","year":"2021","unstructured":"Keller, L., Belloum, Y., Wikman, H. & Pantel, K. Clinical relevance of blood-based ctDNA analysis: Mutation detection and beyond. Br. J. Cancer. 124(2), 345\u2013358. https:\/\/doi.org\/10.1038\/s41416-020-01047-5 (2021).","journal-title":"Br. J. Cancer."},{"issue":"2","key":"47972_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000499931","volume":"14","author":"M Balic","year":"2019","unstructured":"Balic, M., Thomssen, C., W\u00fcrstlein, R., Gnant, M. & Harbeck, N. St. Gallen\/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care (Basel) 14(2), 103\u2013110. https:\/\/doi.org\/10.1159\/000499931 (2019).","journal-title":"Breast Care (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47972-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47972-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47972-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:34:51Z","timestamp":1781134491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47972-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47972"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47972-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study utilized the publicly accessible Charit\u00e9 Breast Cancer Dataset (Mendeley Data,\n                      \n                      ), collected prospectively between November 2016 and March 2021 under approval by the Ethics Committee of Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Germany (Ethics Committee approval number: EA2\/084\/16). The Ethics Committee of Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin waived the requirement for informed consent for secondary analysis of anonymized data, as stipulated under Article 15(8) of the EU General Data Protection Regulation (GDPR), given the retrospective nature of the dataset and the absence of direct patient identifiers. The current study\u2019s reuse of this dataset complies with the original Ethics Committee\u2019s waiver, as no additional patient contact, intervention, or identifiable information was involved. All methods were performed in accordance with relevant guidelines and regulations governing secondary use of anonymized biomedical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"18122"}}